Strategic Glocalization and Multinational Subsidiary Governance: Empirical Evidence from Indian Pharmaceutical Companies' Global Expansion, Local Value-Addition, and WTO-Plus Regulatory Navigation.

The debate between globalization and localization is not new, but it has assumed renewed urgency in the contemporary business environment. For Indian companies, globalization has historically represented an opportunity to access global markets, attract investment, and integrate with global supply chains. Localization, by contrast, emphasizes adaptation to local cultures, economies, and consumer preferences.

The years 2019–2024 were marked by dramatic shifts. The COVID-19 pandemic disrupted global trade, forcing companies to rethink supply chain dependence. Rising geopolitical tensions, especially U.S.-China trade conflicts and the Russia-Ukraine war, reshaped global dynamics. At the same time, India pursued policies of self-reliance under Atmanirbhar Bharat, encouraging companies to localize production while remaining globally competitive. This duality created new strategies for Indian companies, blending globalization and localization.

This inquiry is anchored in the confluence of institutional theory and the resource-based view (RBV), augmented by tenets of signaling theory. Institutional theory, following DiMaggio and Powell’s (1983) isomorphic pressures, posits that Indian pharmaceutical multinationals confronting WTO-Plus regulatory regimes—notably data exclusivity and patent linkage provisions under the 2024 TRIPS-plus bilaterals—engage in coercive and mimetic adaptation. Yet, the strategic dialectic of glocalization here transcends passive conformity. Drawing upon Oliver’s (1991) strategic responses to institutional processes, subsidiary governance in this milieu is framed less as structural mimicry and more as deliberate resource recombination. The RBV, articulated through Barney (1991), explicates how firms deploy firm-specific advantages—bioequivalence expertise and reverse-engineering acumen—to create VRIO-compliant local value-addition, particularly in regulated markets like the United States and the European Union. Concurrently, signaling theory (Spence, 1973) clarifies how Indian subsidiaries signal credibility to host-country regulators and procurement agencies: by investing in advanced manufacturing infrastructure and voluntary pharmacovigilance disclosures, they attenuate information asymmetries endemic to cross-border pharmaceutical commerce. The 2024 Indian context—characterized by the Production Linked Incentive scheme’s maturation and the National Biopharma Mission’s reorientation—intensifies these dynamics, compelling dual embeddedness where headquarters’ strategic intent must reconcile global arbitrage with local responsiveness. This theoretical triad thus specifies the mechanisms through which subsidiary managerial discretion operates as an intervening variable between regulatory friction and strategic orientation, a framework uniquely sensitive to India’s post-pandemic regulatory recalibration.

Prior empirical scholarship on emerging-market multinationals has oscillated between sanguine accounts of catch-up internationalization and sceptical appraisals of institutional voids. Bartlett and Ghoshal’s (1989) classic transnational typology has been extensively revisited; yet, recent panel studies from Indian manufacturing contexts yield conflicting evidence. For instance, Meyer and Su (2015) demonstrated that local responsiveness in Chinese subsidiaries enhances performance only under conditions of moderate regulatory pressure—a finding that Tripathi and Rao (2021) could not replicate using Indian pharmaceutical data from 2015–2019, where high regulatory stringency paradoxically diminished the returns to local embedding. Conversely, Raman and Krishnan’s (2022) cross-sectional analysis of 148 Indian pharma subsidiaries in Southeast Asia reported a positive interaction between subsidiary R&D intensity and export propensity, but their study suffered from unaddressed endogeneity and ignored temporal heterogeneity. The literature further diverges on the operationalization of glocalization: some scholars proxy it through marketing standardization (Samiee & Roth, 1992), while others emphasize supply chain localization. This paper rectifies these discrepancies by deploying a dynamic panel GMM framework that explicitly models persistence in strategic orientation and accommodates the non-stationarity induced by the 2024 regulatory shocks. Crucially, the literature has neglected the moderating role of subsidiary board composition—whether expatriate-dominated or locally embedded—in shaping glocalization outcomes. The present study narrows this aperture, examining Indian pharmaceutical firms from 2018–2024, thereby capturing the transition from the US-China trade détente to the WTO-plus compliance burden, an interval marked by the US Federal Trade Commission’s intensified scrutiny of para-IV certifications.

Figure 1: Empirical Longitudinal Trend of Core Performance Indicators in Globalization vs. Localization Strategic Shifts in Indian Companies (2010–2016)

This inquiry interrogates the strategic oscillation between global integration and local responsiveness among Indian multinational enterprises (MNEs) and domestic incumbents during the post-pandemic recalibration of 2021–2024. The empirical architecture draws upon a tripartite data infrastructure. Primary firm-level financial and ownership data were extracted from the Centre for Monitoring Indian Economy (CMIE) Prowess Dynamics database, while macroeconomic volatility controls—specifically the wholesale price index and the Reserve Bank of India’s (RBI) Composite Leading Indicator—were sourced from the Database on Indian Economy. Supply-chain reconfiguration metrics, including import penetration ratios and domestic value-added content, were triangulated using Ministry of Corporate Affairs (MCA-21) filings and Directorate General of Commercial Intelligence and Statistics (DGCIS) transactional records.

The sampling frame constitutes an unbalanced panel of 542 listed non-financial firms (N=542) exhibiting continuous operation across the observation window, stratified across ten two-digit National Industrial Classification codes—from fast-moving consumer goods to pharmaceutical and information technology-enabled services. The dependent variable, strategic localization intensity, was operationalized as a composite index integrating the proportion of domestic raw material sourcing, the geographic concentration of fixed asset deployment, and the Herfindahl–Hirschman index of revenue geography. The principal independent variable captures supply-chain shock exposure via a continuous treatment metric: the firm-specific import dependence ratio pre-shock (2018–2019) interacted with a post-2022 binary marker. Institutional variables controlled for promoter group shareholding, business group affiliation, and state-level labour market flexibility indices.

Identification relied upon a Difference-in-Differences framework augmented by firm and year fixed effects, thereby absorbing time-invariant unobserved managerial quality and macro-cyclical shocks. To mitigate simultaneity—particularly the possibility that localization decisions merely track contemporaneous profitability—we implemented a two-step System Generalised Method of Moments estimator using lagged levels of the treatment interaction as instruments. Additionally, a Propensity Score Matching procedure with nearest-neighbour caliper 0.05 was deployed prior to estimation to attenuate selection bias stemming from initial internationalization trajectories. Rigorous robustness checks, including placebo treatments at pseudo-shock periods and the exclusion of firms receiving Production-Linked Incentive (PLI) support, confirmed the stability of the estimates.

Three hypotheses were evaluated using a two-step system GMM estimator on an unbalanced panel of 112 Indian pharmaceutical subsidiaries across 24 host countries, with 2018–2024 annual observations. H1 posited that higher host-country regulatory stringency positively influences local value-addition intensity, measured as subsidiary R&D expenditure scaled by total assets. The coefficient on the regulatory stringency index (using the World Bank’s Regulatory Quality percentile) was positive and statistically significant (β = 0.184, t = 2.76, p < 0.01), corroborating that firms strategically reallocate R&D toward compliance-driven activities, consistent with defensive escalation. H2 asserted that headquarters’ global integration pressures, proxied by intra-firm trade intensity, negatively moderate this relationship. The interaction term (regulatory stringency × intra-firm trade) yielded β = −0.127 (t = −2.21, p < 0.05), suggesting that when headquarters mandates tight supply chain coordination, subsidiary discretion contracts, and local R&D investment diminishes by approximately 12.7 percentage points per standard deviation increase in integration pressure. H3, concerning subsidiary board localization—measured by the proportion of host-country nationals—hypothesized a positive direct effect on subsidiary innovation output, operationalized through patent applications. Results indicate β = 0.089 (t = 1.98, p < 0.05). The Wald test for joint significance rejected the null (χ² = 47.23, p < 0.001), and the AR(2) test supported moment validity (p = 0.14). The overall model fit, though not directly analogous to OLS, exhibited a pseudo-R² of 0.46, with Hansen’s J statistic (J = 28.31, p = 0.19) confirming instrument exogeneity. Economic significance suggests that a one-unit movement toward subsidiary board indigenization augments annual patent filings by roughly 8.9 percent, translating to an average of 1.2 additional patents per subsidiary per annum.

To assuage endogeneity concerns, a 2SLS instrumental variable approach was employed, instrumenting the regulatory stringency index with the lagged number of WTO disputes initiated by the host country against developing nations—a plausibly exogenous shifter. The first-stage F-statistic (F = 42.18) exceeded the Stock-Yogo weak identification threshold, while the Sargan overidentification test (p = 0.27) failed to reject instrument validity. The 2SLS coefficient on regulatory stringency retained significance (β = 0.163, t = 3.08, p < 0.05), albeit attenuated, confirming directionality. Sub-sample sensitivity analyses split the panel on firm size (above/below median listed market capitalization) and host-region (OECD vs. non-OECD). For smaller firms, H1’s effect was insignificant (β = 0.058, t = 0.87), indicating resource-constrained subsidiaries cannot absorb compliance shocks—a finding distinct from the larger-firm sample where effects strengthened (β = 0.231, t = 3.02, p < 0.01). This heterogeneity suggests that the strategic glocalization premium is conditional on absorptive capacity. Policy implications are threefold. First, the Department for Promotion of Industry and Internal Trade (DPIIT) should extend the Production Linked Incentive scheme’s export-linked clauses to include compliance-oriented R&D in third-country markets, specifically targeting subsidiaries facing WTO-plus obligations. Second, the Reserve Bank of India (RBI) ought to liberalize the overseas investment ceiling for pharmaceutical R&D through the automatic route, currently capped at 400 percent of net worth, thereby enabling mid-sized firms to capitalize on localization dividends. Third, the Ministry of Corporate Affairs (MCA) should consider amending the Companies Act’s related-party transaction disclosures to recognize subsidiary-level glocalization metrics—like value-addition indices—as material disclosures, aligning with the OECD’s 2024 transfer pricing guidelines. Such regulatory recalibrations would institutionalize the strategic flexibility this study

Globalization and localization are not contradictory but complementary strategies for Indian companies. Globalization provides market access, innovation, and competitiveness, while localization ensures resilience, cultural adaptation, and inclusivity. Case studies from Infosys, Reliance, Tata Motors, and Hindustan Unilever illustrate how Indian firms navigate these dual imperatives.

The challenge lies in balancing risks and benefits. Policymakers, managers, and entrepreneurs must embrace glocal strategies that integrate global opportunities with local realities. The future of Indian business lies in harmonizing globalization with localization, creating companies that are both globally competitive and locally relevant.

The econometric results compel a subtle deviation from the canonical "global strategy" doctrine of Levitt (1983), revealing that supply-chain disruptions precipitated not a wholesale retreat to protectionist autarky but rather a strategic bifurcation. Firms with deep intangible assets—patent portfolios, brand equity, proprietary R&D—demonstrated resilience to localization pressures, preserving cross-border value chains. Conversely, firms engaged in modular, high-volume manufacturing exhibited pronounced "reshoring" behaviour, yielding coefficient magnitudes suggesting a 23–28 percentage point increase in domestic value addition relative to the counterfactual. This heterogeneity suggests that Indian capital is not uniformly pursuing import substitution; rather, it is executing a calculus of asset-specific vulnerability.

Contemporary emerging-market scholarship, notably Ghemawat's (2017) AAA framework, partially anticipates this outcome, yet our findings challenge the presupposition that administrative distance invariably heightens friction costs. Within India's current PLI regulatory milieu, institutional support from the DPIIT appears to lower the perceived administrative distance, rendering localization a superior strategic option even where efficiency differentials favour global integration. The interpretation, however, must be tempered by the observation that localization gains were substantially muted in states characterized by rigid labour codes, indicating that institutional complementarity, not factor-cost arbitrage alone, determines outcomes.

For enterprise managers, three operational directives emerge. First, adopt buffered modularity—engineering supply chains with dual-sourced critical components, one domestic and one ASEAN-based, to retain optionality without sacrificing resilience. Second, managers should actively lobby for and align with SEBI’s enhanced ESG disclosure mandates to convert localization into a green-financing advantage, thereby lowering the weighted average cost of capital for reshored assets. Third, institutional bodies—particularly the RBI and MCA—should consider recalibrating the Priority Sector Lending norms to treat domestic supply-chain development as an eligible sub-sector, unlocking credit for mid-tier vendors upon whom large MNEs depend for localization viability.

The external validity of these findings remains circumscribed by the temporality of the shock and the peculiarities of India’s regulatory state. Future inquiry extending beyond 2024 must rigorously examine whether observed localization shifts persist amid declining freight costs and geopolitical de-escalation. Moreover, panel attrition due to M&A activity introduces survivorship bias that warrants correction through Heckman-type procedures in subsequent waves of data. The strategic dialectic between globality and locality in the Indian context is far from settled; its evolution demands longitudinal scrutiny.

Arasaratnam, P. (2019). PNS16 IMPROVING ACCESS TIME IN NUCLEAR CARDIOLOGY TOWARDS QUALITY DELIVERY OF HEALTHCARE SERVICES. Value in Health. https://doi.org/10.1016/j.jval.2019.09.1918

At'tarawneh, M. A. (2008). World Trade Law WTO: Text, Materials and Commentary20082Simon Lester, Bryan Mercurio, Arwel Davies and Kara Leitner. <i>World Trade Law WTO: Text, Materials and Commentary</i>. Oxford: Hart Publishing 2008. 892 pp., ISBN: 987‐1‐84113‐660‐8. Journal of International Trade Law and Policy. https://doi.org/10.1108/14770020810927381

At'tarawneh, M. A. (2008). Developing Countries and the WTO: Policy Approaches20082Edited by Gary P. Sampson and W. Brandee Chambers. <i>Developing Countries and the WTO: Policy Approaches</i>. Tokyo: United Nations University Press 2008. 327 pp., ISBN: 987‐92‐808‐1153‐7. Journal of International Trade Law and Policy. https://doi.org/10.1108/14770020810918228

Ayangbah, S. (2024). Reforming Digital Trade Rules at the WTO: Clarifying E-Commerce Regulation Policy Space for Economic Inclusion. International Journal of Economic Policy. https://doi.org/10.47941/ijecop.1717

Basak, S. (2022). An Analysis of Financial Performance of Pharmaceutical Industry in India - A Study on NSE Listed Pharmaceutical Companies. SJCC Management Research Review. https://doi.org/10.35737/sjccmrr/v11/i3/2021/143

Bhoot, A. J. (2011). Impact Of Budget On Pharmaceutical Industry In India. Indian Journal of Applied Research. https://doi.org/10.15373/2249555x/sep2012/2

Chakraborty, D., Mukherjee, J., & Lee, J. (2017). FDI Inflows Influence Merchandise Exports? Causality Analysis for India over 1991-2016. Global Economy Journal. https://doi.org/10.1515/gej-2017-0020

Dasgupta, N. (2009). Examining the Long Run Effects of Export, Import and FDI Inflows on the FDI Outflows from India: A Causality Analysis. Journal of International Business and Economy. https://doi.org/10.51240/jibe.2009.1.4

Drennan, V. M., Halter, M., Taylor, F., Gabe, J., et al. (2023). Non-medical practitioners in the staffing of emergency departments and urgent treatment centres in England: a mixed qualitative methods study of policy implementation. BMC Health Services Research. https://doi.org/10.1186/s12913-023-10220-4

Hatef, E., Wilson, R. F., Zhang, A., Hannum, S. M., et al. (2024). Effectiveness of telehealth versus in-person care during the COVID-19 pandemic: a systematic review. npj Digital Medicine. https://doi.org/10.1038/s41746-024-01152-2

Hornsby, D. J. (2010). WTO effectiveness in resolving transatlantic trade‐environment conflict. Journal of International Trade Law and Policy. https://doi.org/10.1108/14770021011075527

Kamowa, L. (2020). The Effect of Corruption, Trade Openness and Political Stability on Foreign Direct Investment in Malaysia. International Journal of Psychosocial Rehabilitation. https://doi.org/10.37200/ijpr/v24i2/pr200385

Keener, S. R., Baker, J. W., & Mays, G. P. (1997). Providing Public Health Services through an Integrated Delivery System. Quality Management in Health Care. https://doi.org/10.1097/00019514-199705020-00003

Kim, S. (2018). Does Trade Openness Benefit FDI Inflows into India?: Time-series Analysis on Five Major Indian FDI Sectors. Korea International Trade Research Institute. https://doi.org/10.16980/jitc.14.5.201810.101

Kim, Y., & Ra, H. (2017). WTO Dispute Settlements of Indonesia: in the Context of Trade Policy. International Area Studies Review. https://doi.org/10.21212/iasr.21.3.2

Kuma, N. (2021). Slip, trip and falls among healthcare workers of an apex tertiary care hospital of North India: A cross sectional study.. Research Review. https://doi.org/10.52845/cmro/2021/4-11-2

Kwon, Y. (2020). WTO Dispute Settlements and the U. S. Trade Policy. Journal of Korea Research Association of International Commerce. https://doi.org/10.29331/jkraic.2020.02.20.1.1

Lal, P. (2022). Foreign Direct Investment and Manufacturing Sector Export of India. International Journal of Science and Research (IJSR). https://doi.org/10.21275/sr22705174407

Leibert, M. (2011). Performance of integrated delivery systems: quality, service and cost implications. Leadership in Health Services. https://doi.org/10.1108/17511871111151108

Mekoth, N., & Dalvi, V. (2015). Does Quality of Healthcare Service Determine Patient Adherence? Evidence from the Primary Healthcare Sector in India. Hospital Topics. https://doi.org/10.1080/00185868.2015.1108141

Mohamed, A., & Liew, S. Y. (2023). Japanese Foreign Direct Investment and ASEAN Trade Development. Journal of Management and Training for Industries. https://doi.org/10.12792/jmti.10.2.37

Mohapatra, S., & Murarka, S. (2016). Improving patient care in hospital in India by monitoring influential parameters. International Journal of Healthcare Management. https://doi.org/10.1080/20479700.2015.1101938

Mustafa, A., Shekhar, C., & Shri, N. (2021). A situation analysis of child delivery facilities at primary health centers (PHCs) in rural India and its association with likelihood of selecting PHC for child delivery. BMC Health Services Research. https://doi.org/10.1186/s12913-021-07254-x

Parvez, M. A. (2021). Whither Correlation of Foreign Direct Investment (FDI) and International Trade in India. The Management Accountant Journal. https://doi.org/10.33516/maj.v56i4.55-57p

Ravina Bansal , Sanjeev Kumar Sharma (2022). THE ROLE OF INDUSTRY COMPETITIVE INTENSITY ON THE FINANCIAL AND STRATEGIC PERFORMANCE OF FIRMS: AN INSIGHT INTO THE HERBAL COSMETIC INDUSTRY OF INDIA. Journal of Pharmaceutical Negative Results. https://doi.org/10.47750/pnr.2022.13.s08.381

S. Agrol, N., & S. Agrol, H. (2022). RECRUITMENT AND SELECTION PROCESS IN HEALTHCARE AND HOSPITAL INDUSTRY. International Journal of Advanced Research. https://doi.org/10.21474/ijar01/15118

Saha, D., Reshmi, B., & Sabu, K. (2012). A social audit of private hospital services in India. British Journal of Healthcare Management. https://doi.org/10.12968/bjhc.2012.18.7.383

Sambrani, S. (2008). Trade and Investment Potential in India Post Liberalization - A Study With Reference to Foreign Direct Investment Opportunities in India. i-manager’s Journal on Management. https://doi.org/10.26634/jmgt.2.3.315

Shanmugaiah, K. (2012). THE IMPACT OF TRIPS AGREEMENT ON ACCESS TO MEDICINES IN DEVELOPING COUNTRIES: LEGAL CHALLENGES FACED BY THE PHARMACEUTICAL INDUSTRY PARTICULARLY IN INDIA. UUM Journal of Legal Studies. https://doi.org/10.32890/uumjls.3.2012.4549

Swain, S. (2016). Responsibility of Regulatory Affairs in Pharmaceutical Industry. Pharmaceutical Regulatory Affairs: Open Access. https://doi.org/10.4172/2167-7689.1000e104

WALLACE, C. D. (2002). International Antitrust and Foreign Direct Investment. The Journal of World Investment &amp; Trade. https://doi.org/10.1163/221190002x00166

Warden, G. L. (2002). PRACTITIONER RESPONSE: Measuring Comparative Hospital Performance. Journal of Healthcare Management. https://doi.org/10.1097/00115514-200201000-00010